FranzXaver Schmidbauer - Brickell Biotech Vice Chairman of the Supervisory Board

BBI
 Stock
  

USD 0.10  0.002  2.04%   

  Chairman
Mr. FranzXaver Schmidbauer has served as Vice Chairman of the Supervisory Board at BBI Buergerliches Brauhaus Immobilien AG since December 31, 2006. Before that, he served as Member of the Supervisory Board at the Company from June 17, 2006
Age: 75  Chairman Since 2006      
720 505-4755  www.ir.brickellbio.com
Schmidbauer is a Businessman. Currently, he serves as Vice Chairman of the Supervisory Board at BHB Brauholding BayernMitte AG and Chairman of the Supervisory Board at VIB Vermoegen AG. He is also Managing Director at FXS Vermoegensverwaltung GmbH. He holds a diploma in Engineering.

Brickell Biotech Management Efficiency

Brickell Biotech has Return on Asset of (79.41) % which means that on every $100 spent on asset, it lost $79.41. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (151.7) %, meaning that it generated no profit with money invested by stockholders. Brickell Biotech management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Invested Capital is estimated to increase to 16.65, while Return on Investment is projected to decrease to (33.96) . Brickell Biotech Assets Non Current are most likely to decrease significantly in the upcoming years. The last year's value of Assets Non Current was reported at 117,000. The current Goodwill and Intangible Assets is estimated to increase to about 407.3 K, while Revenue to Assets are projected to decrease to 0.31.
The company has 69 K in debt with debt to equity (D/E) ratio of 0.0, which may show that the company is not taking advantage of profits from borrowing. Brickell Biotech has a current ratio of 6.03, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Brickell Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Brickell Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Brickell Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Brickell to invest in growth at high rates of return. When we think about Brickell Biotech's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

CHAIRMAN Since

Keith SherinGeneral Electric
2013
David JoyceGeneral Electric
2020
Lawrence CulpGeneral Electric
2018
Jeffrey ImmeltGeneral Electric
2017
Edgar SiaDupont Denemours
N/A
Peter FellnerMereo Biopharma Group
N/A
Albert EilenderAdicet Bio
2018
Tony CaktiongDupont Denemours
N/A
Andrew BryantIntel Corp
2012
William KennardATT Inc
2021
Russell StokesGeneral Electric
2018
Robert ConwayArca Biopharma
2014
Randall StephensonATT Inc
2020
H CulpGeneral Electric
2018
John RiceGeneral Electric
2010
Edward BreenDupont Denemours
2020
Dan HeintzelmanGeneral Electric
2013
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company was founded in 2009 and is headquartered in Boulder, Colorado. Brickell Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people. Brickell Biotech (BBI) is traded on NASDAQ Exchange in USA. It is located in 5777 Central Avenue, Suite 102, Boulder, CO 80301, United States and employs 16 people. Brickell Biotech was previously known as BRICKELL BIOTECH INC and was traded on NASDAQ Exchange under the symbol VICL. Brickell Biotech is listed under Pharmaceutical Products category by Fama And French industry classification.

Brickell Biotech Leadership Team

Elected by the shareholders, the Brickell Biotech's board of directors comprises two types of representatives: Brickell Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Brickell. The board's role is to monitor Brickell Biotech's management team and ensure that shareholders' interests are well served. Brickell Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Brickell Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Petra Riechert, Investor Relations Contact Officer
Ron Schmitz, CFO, Director
Rupert Hackl, Member of the Supervisory Board
Rainer Hettmer, Sole Member of the Management Board
Garth Braun, President CEO, Director
Don Noakes, Vice President - Operations
Josh Wylie, Vice President - Land
Ulrich Wiehle, Investor Relations Contact
Craig Wiebe, Vice President - Exploration
William Macdonald, President Director
Kevin Andrus, Independent Director
FranzXaver Schmidbauer, Vice Chairman of the Supervisory Board
Ludwig Schlosser, Chairman of the Supervisory Board
Jeff Swainson, CFO
Sean Campbell, Director
Joshua Mann, Vice President - Business Development
Ralph Allen, Vice President - Geoscience

Brickell Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Brickell Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Brickell Biotech Investors Sentiment

The influence of Brickell Biotech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Brickell. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Brickell Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Brickell Biotech's short interest history, or implied volatility extrapolated from Brickell Biotech options trading.

Current Sentiment - BBI

Brickell Biotech Investor Sentiment

Greater number of Macroaxis users are currently bullish on Brickell Biotech. What is your opinion about investing in Brickell Biotech? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Pair Trading with Brickell Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brickell Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brickell Biotech will appreciate offsetting losses from the drop in the long position's value.

Brickell Biotech Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Brickell Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brickell Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brickell Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brickell Biotech to buy it.
The correlation of Brickell Biotech is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brickell Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brickell Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brickell Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Brickell Biotech information on this page should be used as a complementary analysis to other Brickell Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Brickell Stock analysis

When running Brickell Biotech price analysis, check to measure Brickell Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brickell Biotech is operating at the current time. Most of Brickell Biotech's value examination focuses on studying past and present price action to predict the probability of Brickell Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brickell Biotech's price. Additionally, you may evaluate how the addition of Brickell Biotech to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Is Brickell Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brickell Biotech. If investors know Brickell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brickell Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
15 M
Quarterly Revenue Growth YOY
4.41
Return On Assets
-0.85
Return On Equity
-1.76
The market value of Brickell Biotech is measured differently than its book value, which is the value of Brickell that is recorded on the company's balance sheet. Investors also form their own opinion of Brickell Biotech's value that differs from its market value or its book value, called intrinsic value, which is Brickell Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brickell Biotech's market value can be influenced by many factors that don't directly affect Brickell Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brickell Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Brickell Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brickell Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.